Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from Stavanger University have provided new data on breast cancer
June 25th, 2009
"Estrogen receptor- (ER) is an important prognostic and predictive marker in breast cancer. ER signaling normally down-regulates expression of Apolipoprotein D (ApoD), a lipocalin that binds, transports or chelates lipophilic ligands, including tamoxifen (TAM)," scientists writing in the journal Acta Oncologica report. "Hence, the co-expression of ApoD may therefore identify clinical relevant subgroups of ER positive breast cancer patients. ApoD, ER, and progesterone receptor (PR) protein expressions were determined by immunohistochemistry (IHC) in primary tumors of 290 patients with operable breast cancer. The median follow-up was 12 years. Patients were...
Source: Women's Health Weekly (2009-06-25)
|
